This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Qiagen (QGEN) Q4 Earnings Lag Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of -1.61% and 0.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?
by Zacks Equity Research
QGEN stays on investors' radar due to its robust expansion of testing menu and benefits from strategic ties.
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strategic Collaborations Aid QGEN Stock Amid Competition
by Zacks Equity Research
QIAGEN invests heavily in research and development to support internal growth, including the menu expansion of its key platforms.
GMAB vs. QGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
GMAB vs. QGEN: Which Stock Is the Better Value Option?
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?
by Zacks Equity Research
BeiGene (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Hologic Hits New 52-Week Low: How to Play the Stock Now?
by Moumi Mondal
HOLX touched a new yearly low this week, reflecting market reaction to its mixed Q1 fiscal 2025 results. Still, the stock offers strong rebound potential.
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
QGEN Stock Might Rise Following Partnership With Genomics England
by Zacks Equity Research
QIAGEN partners with Genomics England to support the United Kingdom's initiative to sequence the genomes of 100,000 newborns with expert-curated genomic content.
New Product Offerings Support QIAGEN's Shares Amid Currency Woes
by Zacks Equity Research
To support internal growth, QIAGEN is investing heavily in R&D for menu expansion of its key platforms.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
QIAGEN Stock Gains Following the Latest Launch of IPA Interpret
by Zacks Equity Research
QGEN announces the launch of IPA Interpret to extend the analysis capabilities of a human-curated knowledge base with AI technology.
Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements
by Zacks Equity Research
QGEN achieves milestone with more than 1,000 EZ2 Connect placements worldwide, contributing to a global installed base of over 5,500 EZ series instruments.
Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
by Zacks Equity Research
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
Here's Why Qiagen (QGEN) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QGEN Stock to Gain From Expanding QIAstat-Dx With New Barcelona Site
by Zacks Equity Research
QIAGEN's new Barcelona site is set to drive QIAstat-Dx's growth in infectious diseases and precision medicine testing.
QGEN Stock Dips Despite Launch of Customized dPCR Assay Design Tools
by Zacks Equity Research
QIAGEN introduces two new customizable dPCR assay design tools featuring advanced design algorithms tailored for diverse microbial applications and custom NGS panels.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.